Role of imaging biomarkers in mutation-driven non-small cell lung cancer

Table 3 Summary of reported clinicopathologic biomarkers in select molecular genotypes in non-small cell lung cancer¹

Clinicopathologic features	EGFR-mutant	ALK-rearranged	ROS1-rearranged	BRAF V600E-mutant	MET exon 14 skipping
Age	Younger	Younger	Younger	No specific age predilection	Older compared to another mutated NSCLC
Race	More common in Asian populations	More common in Caucasian populations	No specific racial predilection	No specific racial predilection	No specific racial predilection
Smoking history	Minimal to no smoking history	Minimal to no smoking history	Minimal to no smoking history	Minimal to no smoking history; positive smoking history in non-V600E mutation	Both smokers and non-smokers
Tumor histology	Adenocarcinoma	Adenocarcinoma	Adenocarcinoma	Adenocarcinoma	Increased incidence of METex14 skipping with sarcomatoid histology

¹Data collected from several sources[40,54,63,65,66,71].